Sol-Gel Technologies has dosed the first patient in a pivotal Phase III clinical trial programme designed to analyse the safety and efficacy of Epsolay (formerly VERED) for the treatment of patients with papulopustular rosacea, also known as subtype II rosacea.

The programme is being carried out following Special Protocol Assessment (SPA) agreements with the US Food and Drug Administration (FDA) regarding the design of the trials.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It includes two randomised, multi-centre, double-blind, vehicle-controlled clinical trials, which are expected to enrol a total of 700 subjects at 50 sites in the US.

Each of the trials expect to include half of the enrolled subjects in a 2:1 ratio of Epsolay in comparison to its vehicle, with a power of greater than 99%.

The trials’ primary efficacy goals are success in Investigator Global Assessment (IGA), measured as a two-grade reduction in IGA on a scale of zero to four with ‘clear’ or ‘almost clear’ at week 12, and a decrease in mean inflammatory lesion count at week 12.

“Epsolay is aimed to address the need for more effective treatments for inflammatory papules and pustules of rosacea, a chronic condition for which patients often have low adherence to current drugs.”

Top-line data from both the trials are slated to be reported next year.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Sol-Gel Technologies CEO Dr Alon Seri-Levy said: “The initiation of our pivotal Phase III clinical programme for Epsolay is an important milestone in our development programme and in introducing our proprietary silica-based microencapsulation delivery system to topical drugs.

“Epsolay is aimed to address the need for more effective treatments for inflammatory papules and pustules of rosacea, a chronic condition for which patients often have low adherence to current drugs.”

Papulopustular rosacea is a chronic, inflammatory skin condition that mostly affects the face.

Epsolay is a once-daily topical cream that features encapsulated benzoyl peroxide, and has been developed using Sol-Gel’s proprietary microencapsulation technology.